Cargando…

Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib

Ponatinib is a small molecule multi‐tyrosine kinase inhibitor clinically approved for anticancer therapy. Molecular mechanisms by which cancer cells develop resistance against ponatinib are currently poorly understood. Likewise, intracellular drug dynamics, as well as potential microenvironmental fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Englinger, Bernhard, Laemmerer, Anna, Moser, Patrick, Kallus, Sebastian, Röhrl, Clemens, Pirker, Christine, Baier, Dina, Mohr, Thomas, Niederstaetter, Laura, Meier‐Menches, Samuel M., Gerner, Christopher, Gabler, Lisa, Gojo, Johannes, Timelthaler, Gerald, Senkiv, Julia, Jäger, Walter, Kowol, Christian R., Heffeter, Petra, Berger, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497038/
https://www.ncbi.nlm.nih.gov/pubmed/32064608
http://dx.doi.org/10.1002/ijc.32924
_version_ 1783583230388076544
author Englinger, Bernhard
Laemmerer, Anna
Moser, Patrick
Kallus, Sebastian
Röhrl, Clemens
Pirker, Christine
Baier, Dina
Mohr, Thomas
Niederstaetter, Laura
Meier‐Menches, Samuel M.
Gerner, Christopher
Gabler, Lisa
Gojo, Johannes
Timelthaler, Gerald
Senkiv, Julia
Jäger, Walter
Kowol, Christian R.
Heffeter, Petra
Berger, Walter
author_facet Englinger, Bernhard
Laemmerer, Anna
Moser, Patrick
Kallus, Sebastian
Röhrl, Clemens
Pirker, Christine
Baier, Dina
Mohr, Thomas
Niederstaetter, Laura
Meier‐Menches, Samuel M.
Gerner, Christopher
Gabler, Lisa
Gojo, Johannes
Timelthaler, Gerald
Senkiv, Julia
Jäger, Walter
Kowol, Christian R.
Heffeter, Petra
Berger, Walter
author_sort Englinger, Bernhard
collection PubMed
description Ponatinib is a small molecule multi‐tyrosine kinase inhibitor clinically approved for anticancer therapy. Molecular mechanisms by which cancer cells develop resistance against ponatinib are currently poorly understood. Likewise, intracellular drug dynamics, as well as potential microenvironmental factors affecting the activity of this compound are unknown. Cell/molecular biological and analytical chemistry methods were applied to investigate uptake kinetics/subcellular distribution, the role of lipid droplets (LDs) and lipoid microenvironment compartments in responsiveness of FGFR1‐driven lung cancer cells toward ponatinib. Selection of lung cancer cells for acquired ponatinib resistance resulted in elevated intracellular lipid levels. Uncovering intrinsic ponatinib fluorescence enabled dissection of drug uptake/retention kinetics in vitro as well as in mouse tissue cryosections, and revealed selective drug accumulation in LDs of cancer cells. Pharmacological LD upmodulation or downmodulation indicated that the extent of LD formation and consequent ponatinib incorporation negatively correlated with anticancer drug efficacy. Co‐culturing with adipocytes decreased ponatinib levels and fostered survival of cancer cells. Ponatinib‐selected cancer cells exhibited increased LD levels and enhanced ponatinib deposition into this organelle. Our findings demonstrate intracellular deposition of the clinically approved anticancer compound ponatinib into LDs. Furthermore, increased LD biogenesis was identified as adaptive cancer cell‐defense mechanism via direct drug scavenging. Together, this suggests that LDs represent an underestimated organelle influencing intracellular pharmacokinetics and activity of anticancer tyrosine kinase inhibitors. Targeting LD integrity might constitute a strategy to enhance the activity not only of ponatinib, but also other clinically approved, lipophilic anticancer therapeutics.
format Online
Article
Text
id pubmed-7497038
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-74970382020-09-25 Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib Englinger, Bernhard Laemmerer, Anna Moser, Patrick Kallus, Sebastian Röhrl, Clemens Pirker, Christine Baier, Dina Mohr, Thomas Niederstaetter, Laura Meier‐Menches, Samuel M. Gerner, Christopher Gabler, Lisa Gojo, Johannes Timelthaler, Gerald Senkiv, Julia Jäger, Walter Kowol, Christian R. Heffeter, Petra Berger, Walter Int J Cancer Cancer Therapy and Prevention Ponatinib is a small molecule multi‐tyrosine kinase inhibitor clinically approved for anticancer therapy. Molecular mechanisms by which cancer cells develop resistance against ponatinib are currently poorly understood. Likewise, intracellular drug dynamics, as well as potential microenvironmental factors affecting the activity of this compound are unknown. Cell/molecular biological and analytical chemistry methods were applied to investigate uptake kinetics/subcellular distribution, the role of lipid droplets (LDs) and lipoid microenvironment compartments in responsiveness of FGFR1‐driven lung cancer cells toward ponatinib. Selection of lung cancer cells for acquired ponatinib resistance resulted in elevated intracellular lipid levels. Uncovering intrinsic ponatinib fluorescence enabled dissection of drug uptake/retention kinetics in vitro as well as in mouse tissue cryosections, and revealed selective drug accumulation in LDs of cancer cells. Pharmacological LD upmodulation or downmodulation indicated that the extent of LD formation and consequent ponatinib incorporation negatively correlated with anticancer drug efficacy. Co‐culturing with adipocytes decreased ponatinib levels and fostered survival of cancer cells. Ponatinib‐selected cancer cells exhibited increased LD levels and enhanced ponatinib deposition into this organelle. Our findings demonstrate intracellular deposition of the clinically approved anticancer compound ponatinib into LDs. Furthermore, increased LD biogenesis was identified as adaptive cancer cell‐defense mechanism via direct drug scavenging. Together, this suggests that LDs represent an underestimated organelle influencing intracellular pharmacokinetics and activity of anticancer tyrosine kinase inhibitors. Targeting LD integrity might constitute a strategy to enhance the activity not only of ponatinib, but also other clinically approved, lipophilic anticancer therapeutics. John Wiley & Sons, Inc. 2020-03-02 2020-09-15 /pmc/articles/PMC7497038/ /pubmed/32064608 http://dx.doi.org/10.1002/ijc.32924 Text en © 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Therapy and Prevention
Englinger, Bernhard
Laemmerer, Anna
Moser, Patrick
Kallus, Sebastian
Röhrl, Clemens
Pirker, Christine
Baier, Dina
Mohr, Thomas
Niederstaetter, Laura
Meier‐Menches, Samuel M.
Gerner, Christopher
Gabler, Lisa
Gojo, Johannes
Timelthaler, Gerald
Senkiv, Julia
Jäger, Walter
Kowol, Christian R.
Heffeter, Petra
Berger, Walter
Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib
title Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib
title_full Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib
title_fullStr Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib
title_full_unstemmed Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib
title_short Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib
title_sort lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib
topic Cancer Therapy and Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497038/
https://www.ncbi.nlm.nih.gov/pubmed/32064608
http://dx.doi.org/10.1002/ijc.32924
work_keys_str_mv AT englingerbernhard lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT laemmereranna lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT moserpatrick lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT kallussebastian lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT rohrlclemens lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT pirkerchristine lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT baierdina lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT mohrthomas lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT niederstaetterlaura lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT meiermenchessamuelm lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT gernerchristopher lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT gablerlisa lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT gojojohannes lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT timelthalergerald lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT senkivjulia lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT jagerwalter lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT kowolchristianr lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT heffeterpetra lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib
AT bergerwalter lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib